Literature DB >> 8364003

Hemodynamic effects of prolonged enoximone infusion (7 days) in patients with severe chronic heart failure.

P Gibelin1, M Dadoun-Dybal, M Candito, J F Robillon, P Morand.   

Abstract

This study investigated the hemodynamic effects and tolerance of infusion of 10 micrograms/kg/min enoximone over 7 days in 12 patients (mean age 64.3 years) with severe chronic heart failure (10 NYHA Class III and 2 Class IV) with idiopathic dilated cardiomyopathy. Hemodynamic parameters were measured 10 minutes, 3 hours, 6 hours, 18 hours, 24 hours, and 7 days after the start of infusion. Catecholamines were assayed before the start of the infusion and on day 7. The heart rate increased on an average from 90.8 +/- 13.7 before infusion to 108.5 +/- 8.2 beats/min (p < 0.05) on day 7 (+20%). The mean arterial pressure decreased by approximately 10% (p < 0.05) between the start and end of the infusion. The pulmonary artery diastolic pressure dropped by a maximum of 30% at the 24th hour (23.1 +/- 5.1 to 16 +/- 5.4 mm Hg; p < 0.01). This decrease remained significant on day 7; the index cardiac was increased a maximum of 40% between the 18th and the 24th hour; p < 0.01). This increase was still significant on day 7 (2.35 +/- 0.44; p < 0.05; +22%). Finally, the decrease in systemic arterial resistance, which reached a maximum of 30% of the 24th hour, persisted on day 7 (-22%); 2076 +/- 451 to 1612 +/- 283 dynes/sec/cm5; p < 0.05). The norepinephrine level did not change significantly (4.5 +/- 1.2 nmol/l before infusion vs. 4.2 +/- 1.1 nmol/l on day 7). Infusion had to be stopped in one patient after 30 minutes because of prolonged severe hypotension.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8364003     DOI: 10.1007/bf00880156

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  16 in total

1.  Enoximone as alternative to mechanical support while awaiting cardiac transplantation.

Authors:  G Dreyfus; B Abry; R Guillemain; V Jebara; C Acar; J P Couetil; C Amrein; C Vulser; A Carpentier
Journal:  Lancet       Date:  1989-01-21       Impact factor: 79.321

Review 2.  New positive inotropic agents in the treatment of congestive heart failure. Mechanisms of action and recent clinical developments. 1.

Authors:  W S Colucci; R F Wright; E Braunwald
Journal:  N Engl J Med       Date:  1986-01-30       Impact factor: 91.245

3.  [Continuous enoximone infusion in patients with severe heart failure in dilated cardiomyopathy, hemodynamic, neurohumoral, chemical laboratory and clinical results].

Authors:  J Neuzner; V Mitrovic; H F Pitschner; H Lissmann; M Schlepper
Journal:  Z Kardiol       Date:  1991-06

4.  Tolerance to dobutamine after a 72 hour continuous infusion.

Authors:  D A Unverferth; M Blanford; R E Kates; C V Leier
Journal:  Am J Med       Date:  1980-08       Impact factor: 4.965

5.  Intermittent, continuous outpatient dobutamine infusion in the management of congestive heart failure.

Authors:  M M Applefeld; K A Newman; W R Grove; F J Sutton; D S Roffman; W P Reed; S E Linberg
Journal:  Am J Cardiol       Date:  1983-02       Impact factor: 2.778

6.  Acute hemodynamic response to low dose enoximone (MDL 17,043): an oral dose-range study.

Authors:  E M Gilbert; M R Bristow; J W Mason
Journal:  Am J Cardiol       Date:  1987-08-14       Impact factor: 2.778

7.  Effect of phosphodiesterase inhibitors on survival of patients with chronic congestive heart failure.

Authors:  M Packer
Journal:  Am J Cardiol       Date:  1989-01-03       Impact factor: 2.778

8.  Acute effects of enoximone in chronic heart failure.

Authors:  F Saborowski; P Peters; M Schneider; W Fehske; H A Dieterich
Journal:  J Cardiovasc Pharmacol       Date:  1989       Impact factor: 3.105

9.  Enoximone as a bridge to heart transplantation: the Utah experience.

Authors:  J B O'Connell; E M Gilbert; D G Renlund; M R Bristow
Journal:  J Heart Lung Transplant       Date:  1991 May-Jun       Impact factor: 10.247

10.  Enoximone (MDL 17,043) for stable, chronic heart failure secondary to ischemic or idiopathic cardiomyopathy.

Authors:  K T Weber; J S Janicki; M C Jain
Journal:  Am J Cardiol       Date:  1986-09-15       Impact factor: 2.778

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.